OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Tasadenoturev active in DIPG	1218
A new standard of care for advanced-stage urothelial carcinoma	888
From little subclones grow mighty oaks	826
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	818
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	810
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	786
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	707
Ecological management of the microbiota in patients with cancer	698
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	615
Hodgkin lymphoma: great progress with room for improvement	609
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	609
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	603
Novel ICI–TKI combination improves HCC outcomes	593
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	523
Current understanding and management of CAR T cell-associated toxicities	512
The emerging roles of circRNAs in cancer and oncology	512
Gut microbiota in colorectal cancer development and therapy	459
From ESMO 2022	450
From the ESMO Congress 2021	442
Mortality is similar with active monitoring	423
Contrasting results with second-line CAR T cells in large B cell lymphoma	371
Ponatinib superior to imatinib in Ph+ ALL	364
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	359
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	358
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	354

Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	334
Understanding and overcoming multidrug resistance in cancer	318
Sacituzumab tirumotecan improves OS in mTNBC	313
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	281
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	278
Humanized mouse models for immuno-oncology research	263
Harnessing cytokines and chemokines for cancer therapy	253
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	239
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	238
Craniospinal irradiation improves leptomeningeal metastasis control	236
Survival benefit with second-line combination in endometrial cancer	235
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	233
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	230
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	230
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	229
Spatial landscapes of cancers: insights and opportunities	229
Improving outcomes in patients with oesophageal cancer	222
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	219
Harnessing big data to characterize immune-related adverse events	219
Biomarkers for immunotherapy of hepatocellular carcinoma	208
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	198
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	198
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	196
New CAPSTONE of SCLC therapy?	187
SHINE a light: frontline ibrutinib for MCL	176
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	173
Women with clinically node negative breast cancer can safely avoid axillary surgery	171
Prospective comparisons support the use of navigational bronchoscopy	168
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	166
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	157
Aumolertinib is effective in NSCLC	157
DREAMseq of therapy for BRAF-mutant melanoma	154
Mitigating acute chemotherapy-associated adverse events in patients with cancer	147
From ESMO 2023: advances in lung cancer	147
Targeting chromosomal instability in patients with cancer	141
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	139
Circulating tumour DNA — looking beyond the blood	136
Long-term outcomes following CAR T cell therapy: what we know so far	136
Benefit with ramucirumab in mesothelioma	122
Response to neoadjuvant endocrine therapy complements recurrence score	119
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	118
Multiomics STEP up in correlative analysis of response to CAR T cells	118
From the ESMO Congress 2023	112
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	110
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	106
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	105
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	101
HAIC-FO improves outcomes in HCC	96
Newly approved cancer drugs in China — innovation and clinical benefit	96
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	94

Enhancing immunotherapy with tumour-responsive nanomaterials	93
Clinical implications of T cell exhaustion for cancer immunotherapy	93
Claudin 18.2 as a novel therapeutic target	93
Combining CAR T cells effective in RRMM	90
Targeted biopsy reduces detection of clinically insignificant cancer	90
Two decades of advances in clinical oncology — lessons learned and future directions	90
Lung cancer in patients who have never smoked — an emerging disease	90
T-DXd effective as second-line therapy in G/GEJ cancers	88
Less-frequent surveillance is noninferior to annual mammography	86
Second-line tarlatamab improves OS in SCLC	86
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	79
Translating biological insights into improved management of endometrial cancer	78
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	75
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	74
Barriers in access to oncology drugs — a global crisis	73
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	70
BrECADD raises the bar in classical Hodgkin lymphoma	69
HSCT prolongs remission of high-risk CTCLs	67
Nirogacestat effective in desmoid tumours	65
Promise with co-administration of CAR T cells	64
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	61
GPRC5D-CAR T cells active in MM	60
Promising OS with oncolytic virotherapy	59
Efficacy of TILs confirmed	58
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	56
Thermal ablation is safer than resection of colorectal liver lesions	56
Cured but breathless: the growing burden of DIILD in cancer survivors	55
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	54
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	54
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	53
Exploiting bacteria for cancer immunotherapy	52
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	51
The current state of the art and future trends in RAS-targeted cancer therapies	50
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	50
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
Neoadjuvant pembrolizumab improves outcomes	46
MSI-H/dMMR mCRC: ICIs in the first line?	44
Pembrolizumab tunes up chemotherapy in cervical cancer	43
LAG3 inhibition improves outcomes	42
Belzutifan is active in VHL-related cancers	42
KN046 shows tolerability and activity in TNBC	39
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	38
Problematic crossovers in cancer drug trials	36
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	33
The emerging roles of γδ T cells in cancer immunotherapy	32
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	31
Integrated MRI-guided radiotherapy — opportunities and challenges	31
CAR T cells induce durable remission of neuroblastoma	31
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	31
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	29
National value-based pricing negotiation for oncology drugs — lessons from China	27
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	27
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	26
Personalizing adjuvant therapy for patients with colorectal cancer	26
Axicabtagene effective in indolent NHL	26